Papadopoulou Lefkothea
Massimo Collino, PhD
Professor of Pharmacology and Toxicology



Ph. D. in “Pharmacology and Toxicology”

 University of Turin (Italy)


Visiting Scientist at The William Harvey Research Institute

Centre for Experimental Medicine, Nephrology & Critical Care, Barts and The London, Queen Mary's School of Medicine and Dentistry, London (UK)


Assistant Professor of Pharmacology and Toxicology

Dept. Drug Science and Technology, University of Turin (Italy)



Dr. Collino was born in Italy, on 19th January 1973. Degree in Pharmaceutical Chemistry and Technology at the University of Turin, Faculty of Pharmacy, March 1998: summa cum laude. Ph. D. in “Pharmacology and Toxicology” at the University of Turin, 1998 – 2002. Visiting Scientist at The William Harvey Research Institute, Centre for Experimental Medicine, Nephrology & Critical Care, Barts and The London, Queen Mary\s School of Medicine and Dentistry, London (UK) in the years 2003-2004. Since 2002 Assistant Professor of Pharmacology, Faculty of Pharmacy, University of Turin. Member of the Italian Society of Pharmacology, the European Biomedical Research Association. , British Pharmacological Society, European Shock Society.

Research Interest

Pathophysiology and the pharmacological therapy of diet-induced insulin resistance and the related cardiovascular risk factors, mainly organ-related ischemic events. Specifically, investigation of the pharmacological potential of selective ligands of the enzyme GSK-3beta, nuclear receptors PPAR and erythropoietin derivatives in in vivo models of ischemic diseases (myocardial infarction, stroke, acute kidney injury), shock (hemorrhagic and endotoxic shock) and diet-induced (mainly sugar-induced) dysmetabolism.


Professional Activities:

Teaching Experience:


  • Teacher of the course of Toxicology (Corso di Studi in CTF, University of Turin) .
  • teacher of the course of Toxicology (Corso di Studi in Tecniche Erboristiche, University of Turin).
  • Tutor of the Ph.D. Program in Pharmaceutical and Biomolecular Sciences (Doctoral School of Sciences and Innovative Technologies, University of Turin) .



  1. Dianzani C, Lombardi G, Collino M, Ferrara C, Cassone MC, Fantozzi R. Priming effects of substance P on calcium changes evoked by interleukin-8 in human neutrophils. J Leukoc Biol. 69:1013-1018, 2001.
  2. Dianzani C., Collino M., Lombardi G., Garbarino G., Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br. J. Pharmacol., 139: 1103-1110, 2003.
  3. Collin M., Rossi A., Cuzzocrea S., Patel NSA., Di Paola R., Hadley J., Collino M, Sautebin L., Thiemermann C.. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J. Leukoc. Biol. 76: 961-970, 2004.
  4. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, Thiemermann C. The selective PPARγ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int., 68: 529-536, 2005.
  5. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Modulation of the oxidative stress and inflammatory response by peroxisome proliferator-activated receptor-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol., 530: 70-80, 2006.
    This paper was awarded by European Journal of Pharmacology as “top-cited research paper published in 2006”.
  6. Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Brit. J. Pharmacol., 147:681-689, 2006.
  7. Dianzani C; Collino M; Gallicchio M; Samaritani S; Signore G; Menicagli R; Fantozzi R Evaluation of in vitro anti-inflammatory activity of some 2-alkyl-4,6-dimethoxy-1,3,5- triazines. J. Pharm. Pharmacol., 58: 219-226, 2006.
  8. Dianzani C*, Collino M*, Gallicchio M, Di Braccio M, Roma G, Fantozzi R Effects of anti-inflammatory [1,2,4]triazolo[4,3-a] [1,8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. J. Inflamm., 3: 4-15, 2006.
    *C. Dianzani and M. Collino are shared first authors of this study.
  9. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med. 41:579-589, 2006.
  10. Patel NS, Cuzzocrea S, Collino M, Chaterjee PK, Mazzon E, Britti D, Yaqoob MM, Thiemermann C. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 562: 148-154, 2007.
  11. Gallicchio M, Rosa AC, Dianzani C, Brucato L, Benetti E, Collino M, Fantozzi R. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). Br J Pharmacol. 2008;153(5):870-8.
  12. Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R. Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. Br J Pharmacol. 2008;153:1153-61.
  13. Murch O, Abdelrahman M, Collino M, Gallicchio M, Benetti E, Mazzon E, Fantozzi R, Cuzzocrea S, Thiemermann C. Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Crit Care Med. 2008; 36:550-9.
  14. Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, Castiglia S, Danni O, Murch O, Dianzani C, Aragno M, Fantozzi R. Treatment with the glycogen synthase kinase-3 inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock. 2008; 30:299-307.
  15. Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Therapeutic Advances in Cardiovascular Disease, 2008; 2:179-197.
  16. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C. Generation of Endogenous Hydrogen Sulfide by Cystathionine Gamma-Lyase limits the Renal Injury and Dysfunction caused by Ischemia/Reperfusion. Lab Invest. 2008; 88:1038-48.
  17. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C. Anti-apoptotic and anti-inflammatory effects of hydrogen sulphide in a rat model of regional myocardial ischaemia and reperfusion” Shock, 2009;31:267-74.
  18. Collino M, Aragno M, Castiglia S, Tomasinelli C, Thiemermann C, Boccuzzi G, Fantozzi R. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes. 2009; 58:235-42.
  19. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int. 2009;55:496-504.
  20. Aragno M, Tomasinelli CE, Vercellinatto I, Catalano MG, Collino M, Fantozzi R, Danni O, Boccuzzi G. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med. 2009;47:1067-74.
  21. Collino M, Castiglia S, Manoni M, Salsini L., Chini J., Masini E., Fantozzi R. Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischemia/reperfusion injury. Thromb Haemost. 2009;102:837-45.
  22. Kapoor A, Collino M, Castiglia S, Fantozzi R, Thiemermann C. Activation of Peroxisome Proliferator-Activated Receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock. 2010;34:117-124.
  23. Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, Thiemermann C, Fantozzi R. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol. 2010; 160:1892-902.
    This paper was highlighted by British Journal of Pharmacology with a commentary (Chatterjee PK., Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol. 2010;160:1889-1891)
  24. Kapoor A, Shintani Y, Collino M, Osuchowski MF, Busch D, Patel NS, Sepodes B, Castiglia S, Fantozzi R, Bishop-Bailey D, Mota-Filipe H, Yaqoob MM, Suzuki K, Bahrami S, Désvergne B, Mitchell JA, Thiemermann C. Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. American Journal of Respiratory and Critical Care Medicine. 2010; 182:1506-1515.
  25. Lovell MJ, Yasin M, Lee KL, Cheung KK, Shintani Y, Collino M, Sivarajah A, Leung KY, Takahashi K, Kapoor A, Yaqoob MM, Suzuki K, Lythgoe MF, Martin J, Munroe PB, Thiemermann C, Mathur A. Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. Atherosclerosis. 2010; 213:67-76.
  26. Miglio G, Rosa AC, Rattazzi L, Grange C, Collino M, Camussi G, Fantozzi R The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br J Pharmacol. 2011;162:111-125.
  27. Collino M, Benetti E, Miglio G, Castiglia S, Rosa AC, Aragno M, Thiemermann C, Fantozzi R. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med. 2011; 50:345-353.
  28. Patel NS, Nandra KK, Brines M, Collino M, Wong WS, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiemermann C. A non-erythropoietic peptide that mimicks the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med. 2011 May 13. doi: 10.2119/molmed.2011.00053.
  29. Benetti E, Patel NS, Collino M. The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications. Endocr Metab Immune Disord Drug Targets. 2011;11:273-84.
  30. Collino M. High dietary fructose intake: Sweet or bitter life? World J Diabetes. 2011; 2:77-81.
  31. Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care. 2011;1:40.
  32. Rosa AC, Rattazzi L, Miglio G, Collino M, Fantozzi R. Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes Inflamm Res. 2012;61:311-317.
  33. Nandra KK, Takahashi K, Collino M, Benetti E, Wong WS, Goh FY, Suzuki K, Patel NS, Thiemermann C. Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat. Shock. 2012;37:592-598.
  34. Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C. Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. Mol Med. 2012;18:719-727.
  35. Collino M., Pini A., Mastroianni R., Benetti E., Lanzi C., Bani D., Chini J., Manoni M., Fantozzi R., Masini E. The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury. J Cell Mol Med 2012; 16: 2196-2207.
  36. Bertinaria M, Rolando B, Giorgis M, Montanaro G, Marini E, Collino M, Benetti E, Daniele PG, Fruttero R, Gasco A. Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile. Eur J Med Chem. 2012;54: 103-12.
  37. Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, Collino M, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Overexpression of histamine H4 receptors in the kidney of diabetic rats. Inflamm Res 2013; 62: 357-365.
  38. Collino M., Benetti E. ,Rogazzo M., Mastrocola R., Yaqoob MY., Aragno M., Thiemermann C, Fantozzi R. (2012). Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR- agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol. 2013;85: 257-264.
  39. Nandra KK, Collino M, Rogazzo M, Fantozzi R, Patel NS, Thiemermann C. Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech. 2013;6: 701-709.
  40. Bangash MN, Patel NS, Benetti E, Collino M, Hinds CJ, Thiemermann C, Pearse RM. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. Crit Care. 2013;17(2): R57.
  41. Khan AI, Coldewey SM, Patel NS, Rogazzo M, Collino M, Yaqoob MM, Radermacher P, Kapoor A, Thiemermann C. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. Dis Model Mech. 2013;6(4): 1021-1030.
  42. Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiemermann C. Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech. 2013;6(4): 1031-1042.
  43. Collino M, Pini A, Mugelli N, Mastroianni R, Bani D, Fantozzi R, Papucci L, Fazi M, Masini E. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. Dis Model Mech. 2013;6(4): 1012-1020.
  44. Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int. 2013;84(3):482-90.
    This paper was highlighted by Kidney International with a commentary (Masaomi Nangaku. Tissue protection by erythropoietin: new findings in a moving field. Kidney International 2013 84:427–429)
  45. Benetti E, Chiazza F, Patel NS, Collino M. The NLRP3 Inflammasome as a Novel Player of the Intercellular Crosstalk in Metabolic Disorders. Mediators Inflamm. 2013;2013: 678627. doi: 10.1155/2013/678627.
  46. Benetti E, Mastrocola R, Rogazzo M, Chiazza F, Aragno M, Fantozzi R, Collino M*, Minetto MA*. High Sugar Intake and Development of Skeletal Muscle Insulin Resistance and Inflammation in Mice: A Protective Role for PPAR- δ Agonism. Mediators Inflamm. 2013;2013: 509502. doi: 10.1155/2013/509502. *M. Collino and M.A.Minetto are shared senior authors of this study.
  47. Collino M, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med. 2013;17: 1494-1505.
  48. Mastrocola R, Collino M, Rogazzo M, Medana C, Nigro D, Boccuzzi G, Aragno M. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol. 2013;305: G398-G407.
  49. Collino M, Rudich A, Konrad D. Mediators of interorgan crosstalk in metabolic inflammation. Mediators Inflamm. 2013;2013: 609096. doi: 10.1155/2013/609096, PubMed ID:24288445, NLM Unique ID:9209001
  50. Chen J, Chiazza F, Collino M; Patel NSA, Coldewey SM, Thiemermann C. Gender dimorphism of the cardiac dysfunction in murine sepsis: Signalling mechanisms and age-dependency. PlosOne. 2014; 9(6): e100631.
  51. Collino M, Mastrocola R, Nigro D, Chiazza F, Aragno M, D'Antona G, Minetto MA. Variability in myosteatosis and insulin resistance induced by high-fat diet in mouse skeletal muscles. Biomed Res Int. 2014; 2014: 569623.
  52. Collino M, Benetti E, Rogazzo M, Chiazza F, Mastrocola R, Nigro D, Cutrin JC, Aragno M, Fantozzi R, Minetto MA, Thiemermann C. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol. 2014 Dec; 171(24): 5802-15.
  53. Bressanello D, Liberto E, Collino M, Reichenbach SE, Benetti E, Chiazza F, Bicchi C, Cordero C. Urinary metabolic fingerprinting of mice with diet-induced metabolic derangements by parallel dual secondary column-dual detection two-dimensional comprehensive gas chromatography. J Chromatogr A. 2014 Sep 26; 1361: 265-76.
  54. Chiazza F, Chegaev K, Rogazzo M, Cutrin JC, Benetti E, Lazzarato L, Fruttero R, Collino M. A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. Oxid Med Cell Longev. 2015; 2015:804659.
  55. Sordi R, Chiazza F, Patel NS, Doyle RA, Collino M, Thiemermann C. 'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury/dysfunction caused by hemorrhagic shock in rats. PLoS One. 2015; 10(4):e0122096.
  56. Mastrocola R, Collino M, Nigro D, Chiazza F, D'Antona G, Aragno M, Minetto MA. Accumulation of advanced glycation end-products and activation of the SCAP/SREBP lipogenetic pathway occur in diet-induced obese mouse skeletal muscle. PLoS One. 2015; 10(3):e0119587.
  57. Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015. pii: S0163-7258(15)00059-5. doi: 10.1016/j.pharmthera.2015.02.005.